Pretreatment Neutrophil-to-Lymphocyte Ratio Can Predict the Prognosis in Bladder Cancer Patients Who Receive Gemcitabine and Nedaplatin Therapy.
about
Combined Detection of Preoperative Neutrophil-to-Lymphocyte Ratio and CEA as an Independent Prognostic Factor in Nonmetastatic Patients Undergoing Colorectal Cancer Resection Is Superior to NLR or CEA AlonePredictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer.Prognostic value of neutrophil-to-lymphocyte ratio in urothelial carcinoma of the upper urinary tract and bladder: a systematic review and meta-analysis.
P2860
Pretreatment Neutrophil-to-Lymphocyte Ratio Can Predict the Prognosis in Bladder Cancer Patients Who Receive Gemcitabine and Nedaplatin Therapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 September 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pretreatment Neutrophil-to-Lym ...... tabine and Nedaplatin Therapy.
@en
Pretreatment Neutrophil-to-Lym ...... tabine and Nedaplatin Therapy.
@nl
type
label
Pretreatment Neutrophil-to-Lym ...... tabine and Nedaplatin Therapy.
@en
Pretreatment Neutrophil-to-Lym ...... tabine and Nedaplatin Therapy.
@nl
prefLabel
Pretreatment Neutrophil-to-Lym ...... tabine and Nedaplatin Therapy.
@en
Pretreatment Neutrophil-to-Lym ...... tabine and Nedaplatin Therapy.
@nl
P2093
P2860
P50
P356
P1476
Pretreatment Neutrophil-to-Lym ...... tabine and Nedaplatin Therapy.
@en
P2093
Hiroki Ito
Jun-Ichi Teranishi
Kazuhide Makiyama
Masahiro Yao
Noboru Nakaigawa
Nobuhiko Mizuno
Ryo Kasahara
Shinji Ohtake
Susumu Umemoto
Yasuhide Miyoshi
P2860
P304
P356
10.1155/2016/9846823
P407
P577
2016-09-08T00:00:00Z